Abstract
Kolorektal saraton onkokoloproktologiyada dolzarb muammolardan biri bo‘lib qolmoqda va havf omillarini, shakllanish mexanizmlarini, hamda kasallikni prognozlashda asosiy roli bo‘lgan genetik tarkibini o‘rganish borasida faol harakatlani amalga oshirilishni talab qiladi. Ushbu maqolada kolorektal saratonni saklllanish molekulyar mexanizmlari, adenomani transformatsiyalanish omillari, kasallik patogenezi va uning mjlekular tabiati tahlil qilingan. Transkriptsion signaturaga asoslangan podtiplar kasallikni to‘liq aniqlashtirish va takomillashtirishga imkon beradi.
Shu bilan birgakasallikni turiga xos davolash usullarini ishlab chiqish haqida tushuncha beradi, bu esa o‘z navbatida kasallikni yanada samarali davolashga yordam bo‘ladi.
References
Агейкина Н.В., Дуванский В.А., Князев М.В., Мальков П.Г, Данилова Н.В., Харлова О.А. Альтернативный путь развития колоректального рака. Гистогенетические и молекулярные особенности зубчатых поражений. Экспериментальная и клиническая гастроэнтерология. 2014:(7(107)):4-12
Всемирная организация здравоохранения. Рак. Информационный бюллетень. - 2021. https://www.who.int/ru/news-room/fact-sheets/detail/cancer/
Демидова Д.А. Колоректальный рак: учеб. пособие / Под ред. Д. А. Демидова; ФГБОУ ВО УГМУ Минздрава России. - Екатеринбург: Издательство УГМУ, 2021 -60 с
Кит О.И., Дженкова Е.А., Мирзоян Э.А., Геворкян Ю.А., Сагакянц А.Б., Тимошкина Н.Н., Каймакчи О.Ю., Каймакчи Д.О., Толмах Р.Е., Дашков А.В., Колесников В.Е., Милакин А.Г., Полуэктов С.И. Молекулярно-генетическая классификация подтипов колоректального рака: современное состояние проблемы. Южно-Российский онкологический журнал. 2021; 2(2): 50-56
Мозеров С.А., Комин Ю.А., Новиков Н.Ю., Южаков В.В., Пашкин С.Б., Мозерова Е.С. Опухолевый ответ на неоадьювантную терапию при колоректальном раке. Журнал научных статей здоровье и образование в XXI веке. 2018:20(4):99-108
An N., Zhao C., Yu Z., Yang X. Identification of prognostic genes in colorectal cancer through transcription profiling of multi-stage carcinogenesis. Oncol. Lett. 2019;17: 432–441
Aoki K., Taketo M.M. Adenomatous polyposis coli (APC): A multi-functional tumor suppressor gene. J. Cell Sci. 2007;120: 3327–3335
Bogaert J., Prenen H. Molecular genetics of colorectal cancer. Ann. Gastroenterol. 2014;27: 9–14;
Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138: –2087
Cheng T.H.T., Gorman M., Martin L., Barclay E., Casey G., Saunders B., Thomas H., Clark S., Tomlinson I. Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP. Eur. J. Hum. Genet. 2015;23: 260–263
Christie M., Jorissen R.N., Mouradov D., Sakthianandeswaren A., Li S., Day F., Tsui C., Lipton L., Desai J., Jones I.T., et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Oncogene. 2013;32: 4675–4682
Corcoran R.B., André T., Atreya C.E., Schellens J.H.M., Yoshino T., Bendell J.C., Hollebecque A., McRee A.J., Siena S., Middleton G., et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF(V600E)-Mutant Colorectal Cancer. Cancer Discov. 2018;8: 428–443
Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61: 759–767.
Frouws M.A., Reimers M.S., Swets M., Bastiaannet E., Prinse B., van Eijk R., Lemmens V.E.P.P., van Herk-Sukel M.P.P., van Wezel T., Kuppen P.J.K., et al. The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PLoS ONE. 2017;12: 1–12
Grady W.M., Markowitz S.D. Genetic and Epigenetic Alterations in Colon Cancer. Ann. Rev. Genom. Hum. Genet. 2002; 3: 101
Hanon B.M., Al-Mohaimen Mohammad N.A., Mahmood A.S. CpG Island Methylator Phenotype (CIMP) Correlation with Clinical and Morphological Feature of Colorectal Cancer in Iraq patients. Pan Arab J. Oncol. 2015;8: 6–13
He L., Lu N., Dai Q., Zhao Y., Zhao L., Wang H., Li Z., You Q., Guo Q. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013;312: 36–47
He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science. 1998;281: 1509–1512
Kosmidou V., Oikonomou E., Vlassi M., Avlonitis S., Katseli A., Tsipras I., Mourtzoukou D., Kontogeorgos G., Zografos G., Pintzas A. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. Hum. Mutat. 2014;35: 329–340
Le Marchand L., Wilkens L.R., Hankin J.H., Kolonel L.N., Lyu L.-C. A case-control study of diet and colorectal cancer in a multiethnic population in Hawaii (United States): Lipids and foods of animal origin. Cancer Causes Control. 2017;8: 637–648
Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W., Jones S., Sjöblom T., Park B.H., Parsons R., et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. USA. 2008;105: 16224–16229
Lenz H.J.J., Van Cutsem E., Limon M.L., Wong K.Y., Hendlisz A., Aglietta M., Garcia-Alfonso P., Neyns B., Luppi G., Cardin D., et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) Ann. Oncol. 2018;29: vol.714
Lin J.K., Chang S.C., Yang Y.C., Li A.F. Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann. Surg. Oncol. 2003;10: 1086–1094;
Luebeck E.G., Moolgavkar S.H. Multistage carcinogenesis and the incidence of colorectal cancer. Proc. Natl. Acad. Sci. USA. 2002;99: 15095
Manes M., Garcia-Gomes M.d.S.A., Sandini T.M., Zaccarelli-Magalhães J., Florio J.C., Alexandre-Ribeiro S.R., Wadt D., Bernardi M.M., Massironi S.M.G., Mori C.M.C. Behavioral and neurochemical characterization of the mlh mutant mice lacking otoconia. Behav. Brain Res. 2019;359: 958–966
Manthravadi S., Sun W., Saeed A. Prognostic impact of BRAF V600E mutation in patients with non-metastatic colorectal cancer with microsatellite instability: A systematic review and meta-analysis. J. Clin. Oncol. 2018;36: 3597
Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268: 1336–1338
Pronobis M.I., Rusan N.M., Peifer M. A novel GSK3-regulated APC:Axin interaction regulates Wnt signaling by driving a catalytic cycle of efficient βcatenin destruction. Elife. 2015;4: e08022
Puccini A., Berger M.D., Naseem M., Tokunaga R., Battaglin F., Cao S., Hanna D.L., McSkane M., Soni S., Zhang W., et al. Colorectal cancer: Epigenetic alterations and their clinical implications. BBA Rev. Cancer. 2017;1868: 439–448
Roth A.D., Tejpar S., Delorenzi M., Yan P., Fiocca R., Klingbiel D., Dietrich D., Biesmans B., Bodoky G., Barone C., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 2019;28: 466–474
Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304: 554
Schwarzenbach H. Loss of Heterozygosity. In: Maloy S., Hughes K., editors. Brenner’s Encyclopedia of Genetics. 2nd ed. Academic Press; San Diego, CA, USA: 2013. pp. 271–273
Shimada Y., Tajima Y., Nagahashi M., Ichikawa H., Oyanagi H., Okuda S., Takabe K., Wakai T. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. J. Surg. Res. 2018;232: 72–81
Suzuki H., Yamamoto E., Maruyama R., Niinuma T., Kai M. Biological significance of the CpG island methylator phenotype. Biochem. Biophys. Res. Commun. 2014;455: 35–42
Tabernero J., Geel R.V., Guren T.K., Yaeger R.D., Spreafico A., Faris J.E., Yoshino T., Yamada Y., Kim T.W., Bendell J.C., et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) J. Clin. Oncol. 2016;34: 3544
Thiagalingam S., Lengauer C., Leach F.S., Schutte M., Hahn S.A., Overhauser J., Willson J.K., Markowitz S., Hamilton S.R., Kern S.E., et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 1996;13: 343–346
Tosi F., Magni E., Amatu A., Mauri G., Bencardino K., Truini M., Veronese S., De Carlis L., Ferrari G., Nichelatti M., et al. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Clin. Colorectal Cancer. 2017;16: e153–e163
Tsang A.H., Cheng K.H., Wong A.S., Ng S.S., Ma B.B., Chan C.M., Tsui N.B., Chan L.W., Yung B.Y., Wong S.C. Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World J. Gastroenterol. 2014;20: 3847–3857
Van Geel R., Tabernero J., Elez E., Bendell J.C., Spreafico A., Schuler M., Yoshino T., Delord J.P., Yamada Y., Lolkema M.P., et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017;7: 610–619
Vaqué J.P., Martínez N., Varela I., Fernández F., Mayorga M., Derdak S., Beltrán S., Moreno T., Almaraz C., De las Heras G., et al. Colorectal Adenomas Contain Multiple Somatic Mutations That Do Not Coincide with Synchronous Adenocarcinoma Specimens. PLoS ONE. 2015;10: 1–12
Wang Y., Liu D., Jin X., Song H., Lou G. Genome-wide characterization of aberrant DNA methylation patterns and the potential clinical implications in patients with endometrial cancer. Pathol. Res. Pract. 2019;215: 137–143
Wei W., Chua M.S., Grepper S., So S.K. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol. Cancer. 2011;10: 16
Wirtzfeld D.A., Petrelli N.J., Rodriguez-Bigas M.A. Hamartomatous polyposis syndromes: Molecular genetics, neoplastic risk, and surveillance recommendations. Ann. Surg. Oncol. 2021;8: 319–327;
Xie J., Itzkowitz S.H. Cancer in inflammatory bowel disease. World J. Gastroenterol. 2018;14: 378–389
Xie Y.-H., Chen Y.-X., Fang J.-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 2020;5: 22
Lim D.R., Kuk J.K., Kim T., Shin E.J. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? Medicine (Baltimore). 2017 Oct;96(42): e8241.